富沢 雄二¹, Paul Friedemann², Flanagan Eoin P.³, Kumpfel Tania⁴, Marignier Romain⁵, 藤原 一男⁶, Hemingway Cheryl⁷, Vodopivec Ivana⁸, Stokmaier Daniela⁸, Weber Kristina⁸, Levy Michael⁹ (1.順天堂大学医学部附属順天堂医院 脳神経内科, 2.Charite-Universitatsmedizin Berlin, 3.Mayo Clinic, 4.Institute of Clinical Neuroimmunology, University Hospital, LMU, Munich, 5.The University Hospital of Lyon, 6.福島県立医科大学 多発性硬化症治療学講座, 7.GOSH and ICH, London, 8.Roche, 9.MGH)

She Dewei¹, Lindsey John W.², Bernitsas Evanthia³, Komorita Naruyasu⁴, Cree Bruce A C.⁵ (1.Horizon Therapeutics, 2.Division of Multiple Sclerosis and Neuroimmunology, University of Texas Health Science Center at Houston, 3.Multiple Sclerosis Center, Wayne State School of Medicine, 4.Mitsubishi Tanabe Pharma Corporation, 5.UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco)

中嶋 秀人¹, Abboud Hesham², Irani Sarosh R.³, Lee Soon-tae⁴, Piquet Amanda⁵, Pittock Sean J.⁶, Yeh Ann E.⁷, Overell James⁸, Rajan Sharmila⁹, El-Khairi Muna¹⁰, Gelfand Jeffrey M.¹¹ (1.日本大学医学部 内科学系神経内科学分野, 2.UH Cleveland Medical Center, 3.NDCN, Oxford University, 4.Seoul National University Hospital, 5.University of Colorado, 6.Mayo Clinic, 7.SickKids, University of Toronto, 8.F. Hoffmann-La Roche Ltd., 9.Genentech, Inc., 10.Roche Products Ltd., 11.UCSF)

横田 優樹, 廣瀬 聡, 原 誠, 中嶋 秀人 (日本大学医学部内科学系神経内科学分野)